Literature DB >> 1359693

The protective efficacy of pili from different strains of Moraxella bovis within the same serogroup against infectious bovine keratoconjunctivitis.

A W Lepper1, L J Moore, J L Atwell, J M Tennent.   

Abstract

Three groups of ten calves were each immunised with a total of 400 micrograms pili prepared from three separate strains of Moraxella bovis in Alhydrogel-oil adjuvant as two divided, equal doses 21 days apart. Groups 1 and 2 each received a monovalent vaccine made from strain 4L and S276R respectively, which belonged to pili serogroup A. Group 3 received vaccine made from pili of strain Maff1, belonging to serogroup F. A further group of ten calves served as non-vaccinated controls. Calves in groups 1 and 2 had developed serogroup A-specific antibody and those in group 3 developed serogroup F-specific antibody, and some evidence of cross-reacting antibody was also detected when measured by an agglutination test using formalin-killed piliated cells of serogroup A strain 4L. Although antibody titres measured against purified pili by ELISA were highest with homologous serogroup antigens, cross-reactive titres to shared epitopes of M. bovis pili were also detected by this method. Ocular challenge of the 40 calves with virulent M. bovis of serogroup A strain S276R was carried out 14 days after the second vaccine dose. All non-vaccinated calves developed infectious bovine keratoconjunctivitis (IBK). The percentage protection in groups 1 (strain 4L) and 2 (strain S276R) was 60% and 80% respectively (P less than 0.05), with mean lesion scores of 0.7 and 0.3 out of a possible 6.0. The percentage protection of calves in group 3 (strain Maff1) was only 30%, with a mean lesion score of 1.4 compared with 2.2 for non-vaccinated controls. The present findings, together with other evidence indicating that immunity to IBK is serogroup-specific, suggest that inclusion of pili from one representative strain from each of the seven Australian and British serogroups in a polyvalent, subunit vaccine should effectively protect the majority of cattle against IBK caused by most field strains of M. bovis encountered in Australia and the United Kingdom.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359693     DOI: 10.1016/0378-1135(92)90104-2

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  7 in total

1.  Evaluation of responses to vaccination of Angus cattle for four viruses that contribute to bovine respiratory disease complex.

Authors:  L M Kramer; M S Mayes; E Fritz-Waters; J L Williams; E D Downey; R G Tait; A Woolums; C Chase; J M Reecy
Journal:  J Anim Sci       Date:  2017-11       Impact factor: 3.159

2.  The type IV pilin of Burkholderia mallei is highly immunogenic but fails to protect against lethal aerosol challenge in a murine model.

Authors:  Paula J Fernandes; Qin Guo; David M Waag; Michael S Donnenberg
Journal:  Infect Immun       Date:  2007-04-02       Impact factor: 3.441

3.  Whole genome sequencing of Moraxella bovis strains from North America reveals two genotypes with different genetic determinants.

Authors:  Emily L Wynn; Matthew M Hille; John Dustin Loy; Gennie Schuller; Kristen L Kuhn; Aaron M Dickey; James L Bono; Michael L Clawson
Journal:  BMC Microbiol       Date:  2022-10-21       Impact factor: 4.465

4.  Antigenic relationships of Moraxella bovis isolates recovered from outbreaks of infectious bovine keratoconjunctivitis in Argentina, Brazil, and Uruguay between 1983 and 2000.

Authors:  Fabrício Rochedo Conceição; Fernando Paolicchi; Ana Lia Cobo; Carlos Gil-Turnes
Journal:  Can J Vet Res       Date:  2003-10       Impact factor: 1.310

5.  Type IV fimbrial subunit protein ApfA contributes to protection against porcine pleuropneumonia.

Authors:  Lenka Sadilkova; Jiri Nepereny; Vladimir Vrzal; Peter Sebo; Radim Osicka
Journal:  Vet Res       Date:  2012-01-12       Impact factor: 3.683

6.  Whole genome sequencing of Moraxella bovoculi reveals high genetic diversity and evidence for interspecies recombination at multiple loci.

Authors:  Aaron M Dickey; Gennie Schuller; J Dustin Loy; Michael L Clawson
Journal:  PLoS One       Date:  2018-12-17       Impact factor: 3.240

7.  A Five Year Randomized Controlled Trial to Assess the Efficacy and Antibody Responses to a Commercial and Autogenous Vaccine for the Prevention of Infectious Bovine Keratoconjunctivitis.

Authors:  Matthew M Hille; Matthew L Spangler; Michael L Clawson; Kelly D Heath; Hiep L X Vu; Rachel E S Rogers; John Dustin Loy
Journal:  Vaccines (Basel)       Date:  2022-06-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.